European Journal of Inflammation (Mar 2024)

Evaluation of circulating CD4CD25CD127 regulatory T cells in newly diagnosed hepatitis C-infected patients

  • Morvarid Asadipour,
  • Soolmaz Khansalar,
  • Fatemeh Rezaei Kahmini,
  • Mahsa Eshkevar Vakili,
  • Mohammad Reza Ataollahi,
  • Mohammad Ali-Hassanzadeh,
  • Keivan Shams,
  • Zahra Faghih,
  • Kurosh Kalantar

DOI
https://doi.org/10.1177/1721727X241242701
Journal volume & issue
Vol. 22

Abstract

Read online

Objectives Hepatitis C virus (HCV) is one of the most global health problems with 2.5% prevalence worldwide. It seems that regulatory T (Treg) cells, which are able to modulate the host immune responses, play a substantial role in the immunopathogenesis of HCV infection. In this study, we evaluated the distribution of Treg cells in HCV-infected patients and its correlation with viral load and clinical manifestations. Methods Peripheral blood mononuclear cells (PBMCs) were collected from 14 newly diagnosed HCV-infected patients and 23 age- and sex-matched healthy subjects, and the frequency of CD4+CD25+CD127−/low Treg cells was determined by flow cytometry. Results Our results showed that the mean level of CD4+CD25+CD127−/low Treg cells in HCV-infected patients was significantly higher than that in healthy control subjects (8.2 ± 1.48% vs 5.4 ± 0.36%, p < .05). However, there was no statistical correlation between Treg cells frequency and viral load or clinical manifestations. Conclusion A higher proportion of Treg cells in HCV-infected patients might indicate their critical role in viral persistence and candidate them as a new target of immunotherapy to improve antiviral immunity.